Synthesis and Evaluation of Anticancer Natural Product Analogues Based on Angelmarin: Targeting the Tolerance towards Nutrient Deprivation
Dr. Jakob Magolan
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorNathan B. P. Adams
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorHiroko Onozuka
Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 (Japan)
Search for more papers by this authorDr. Natasha L. Hungerford
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorProf. Hiroyasu Esumi
Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 (Japan)
Search for more papers by this authorCorresponding Author
Dr. Mark J. Coster
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001Search for more papers by this authorDr. Jakob Magolan
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorNathan B. P. Adams
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorHiroko Onozuka
Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 (Japan)
Search for more papers by this authorDr. Natasha L. Hungerford
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Search for more papers by this authorProf. Hiroyasu Esumi
Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 (Japan)
Search for more papers by this authorCorresponding Author
Dr. Mark J. Coster
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001
Eskitis Institute for Cell and Molecular Therapies (N75), Griffith University, Nathan Campus, Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia), Fax: (+61) 7 3735 6001Search for more papers by this authorGraphical Abstract
Inspired by nature: Angelmarin is an anticancer natural product with potent antiausterity activity, that is, selective cytotoxicity towards nutrient-deprived, resistant cancer cells. Through structure–activity relationship studies, three analogues were identified as lead compounds for the develpoment of molecular probes for the investigation of the mode of action and biological targets of the antiausterity compounds.
Supporting Information
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
| Filename | Description |
|---|---|
| cmdc_201100564_sm_miscellaneous_information.pdf3.6 MB | miscellaneous_information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1R. M. Sutherland, Science 1988, 240, 177–184.
- 2P. Vaupel, F. Kallinowski, P. Okunieff, Cancer Res. 1989, 49, 6449–6465.
- 3K. Koito, T. Namieno, T. Nagakawa, K. Morita, AJR, Am. J. Roentgenol. 1997, 169, 1263–1267.
- 4K. Ranniger, R. M. Saldino, Radiology 1966, 86, 470–474.
- 5N. A. Yassa, J. Yang, S. Stein, M. Johnson, P. Ralls, J. Clin. Ultrasound 1997, 25, 473–480.
10.1002/(SICI)1097-0096(199711/12)25:9<473::AID-JCU2>3.0.CO;2-K CASPubMedWeb of Science®Google Scholar
- 6T. Y. Reynolds, S. Rockwell, P. M. Glazer, Cancer Res. 1996, 56, 5754–5757.
- 7J. Yuan, L. Narayanan, S. Rockwell, P. M. Glazer, Cancer Res. 2000, 60, 4372–4376.
- 8J. Yun, A. Tomida, K. Nagata, T. Tsuruo, Oncol. Res. 1995, 7, 583–590.
- 9A. Tomida, J. Yun, T. Tsuruo, Int. J. Cancer 1996, 68, 391–396.
10.1002/(SICI)1097-0215(19961104)68:3<391::AID-IJC19>3.0.CO;2-B CASPubMedWeb of Science®Google Scholar
- 10J. Folkman, N. Engl. J. Med. 1971, 285, 1182–1186.
- 11D. E. Richard, E. Berra, J. Pouyssegur, Biochem. Biophys. Res. Commun. 1999, 266, 718–722.
- 12P. E. Thorpe, Clin. Cancer Res. 2004, 10, 415–427.
- 13W. E. Fisher, D. H. Berger, Int. J. Gastrointest. Cancer 2003, 33, 79–88.
- 14J. B. Fleming, R. A. Brekken, J. Cell. Biochem. 2003, 90, 492–501.
- 15M. Korc, Mol. Cancer 2003, 2, 8.
- 16D. Wei, X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang, H. Q. Xiong, J. L. Abbruzzese, K. Xie, Oncogene 2003, 22, 319–329.
- 17A. Masamune, K. Kikuta, T. Watanabe, K. Satoh, M. Hirota, T. Shimosegawa, Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G 709–717.
- 18K. Izuishi, K. Kato, T. Ogura, T. Kinoshita, H. Esumi, Cancer Res. 2000, 60, 6201–6207.
- 19J. Magolan, M. J. Coster, Curr. Drug Delivery 2010, 7, 355–369.
- 20H. Esumi, J. Lu, Y. Kurashima, T. Hanaoka, Cancer Sci. 2004, 95, 685–690.
- 21J. Lu, S. Kunimoto, Y. Yamazaki, M. Kaminishi, H. Esumi, Cancer Sci. 2004, 95, 547–552.
- 22S. Awale, J. Lu, S. K. Kalauni, Y. Kurashima, Y. Tezuka, S. Kadota, H. Esumi, Cancer Res. 2006, 66, 1751–1757.
- 23P. Turner, E. Griffin, J. Whatmore, M. Shipman, Org. Lett. 2011, 13, 1056–1059.
- 24T. Devji, C. Reddy, C. Woo, S. Awale, S. Kadota, D. Carrico-Moniz, Bioorg. Med. Chem. Lett. 2011, 21, 5770–5773.
- 25S. Awale, E. M. Nakashima, S. K. Kalauni, Y. Tezuka, Y. Kurashima, J. Lu, H. Esumi, S. Kadota, Bioorg. Med. Chem. Lett. 2006, 16, 581–583.
- 26N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, J. Nat. Prod. 2007, 70, 1582–1587.
- 27N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, Bioorg. Med. Chem. Lett. 2008, 18, 4688–4691.
- 28N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, Bioorg. Med. Chem. 2008, 16, 8653–8660.
- 29N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, Chem. Pharm. Bull. 2008, 56, 491–496.
- 30S. Awale, F. Li, H. Onozuka, H. Esumi, Y. Tezuka, S. Kadota, Bioorg. Med. Chem. 2008, 16, 181–189.
- 31F. Li, S. Awale, Y. Tezuka, S. Kadota, Bioorg. Med. Chem. 2008, 16, 5434–5440.
- 32S. Awale, T. Miyamoto, T. Z. Linn, F. Li, N. N. Win, Y. Tezuka, H. Esumi, S. Kadota, J. Nat. Prod. 2009, 72, 1631–1636.
- 33F. Li, S. Awale, H. Zhang, Y. Tezuka, H. Esumi, S. Kadota, J. Nat. Prod. 2009, 72, 1283–1287.
- 34J. Magolan, M. J. Coster, J. Org. Chem. 2009, 74, 5083–5086.
- 35H. Jiang, Y. Hamada, Org. Biomol. Chem. 2009, 7, 4173–4176.
- 36E. B. J. Harris, M. G. Banwell, A. C. Willis, Tetrahedron Lett. 2011, 52, 6887–6889.
- 37D. J. Clarke, R. S. Robinson, Tetrahedron 2002, 58, 2831–2837.
- 38Compound 9 was inactive in the antiausterity assay. Six analogues (8 a,g,h,k,p,s) could not be separated from 9 via column chromatography (see supporting information). In these cases, a mixture of the analogue and 9 (minor component, composition determined by 1H NMR) was evaluated in the assay and the results were corrected accordingly.
- 39H. Zhao, C. Lee, P. Sai, Y. H. Choe, M. Boro, A. Pendri, S. Guan, R. B. Greenwald, J. Org. Chem. 2000, 65, 4601–4606.
- 40W. A. Henne, D. D. Doorneweerd, A. R. Hilgenbrink, S. A. Kularatne, P. S. Low, Bioorg. Med. Chem. Lett. 2006, 16, 5350–5355.
- 41S. B. Damle, Chem. Eng. News 1993, 71, 4–5.
- 42Compound 8 b was prepared via acetylation of (±)-angelmarin (6), as detailed in the Supporting Information.
Citing Literature
